As the U.S. pharmaceutical industry breathes a collective sigh of relief, Adents is urging pharma manufacturers to take full advantage of the Drug Supply Chain Security Act’s one-year enforcement postponement.
In order to read this article, you must be a Packaging Europe subscriber. By becoming a subscriber, you get access to unmissable exclusive content like this, as well as enhanced personalisation options. The good news is that it’s completely free and very simple to subscribe - click the button below to learn more.
—>